Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Partner Therapeutics Inc. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is handled by 1 distinct examiner and 1 distinct art unit, indicating a specific technical focus for the pending application. Having 1 distinct examiner means that the prosecution strategy can be tailored to the specific preferences and history of that individual. This focus can lead to efficient communication and a clearer path toward patent allowance if the examiner's concerns are met.
The busiest examiner for the portfolio is ABBAS, SYED JARAR, who is assigned the 1 busiest examiner pending office action. This examiner is the official currently reviewing the pending work, so their perspective on the biotechnology and pharmaceutical technology is critical. Because there is 1 distinct examiner and 1 distinct art unit, the prosecution does not have to account for different standards across multiple units. Resolving the 1 pending office action will require a direct and focused response to the specific issues identified by this examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBAS, SYED JARAR | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033252 | GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR MUTANTS | ABBAS, SYED JARAR | 15d |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18033252 | GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR MUTANTS | ABBAS, SYED JARAR | 1674 | §112DP | Final Rejection | 15d | Pending | Apr 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial